Details for New Drug Application (NDA): 204325
✉ Email this page to a colleague
NDA 204325 describes ADZENYS ER, which is a drug marketed by Neos Theraps Inc and is included in one NDA. There are three patents protecting this drug. Additional details are available on the ADZENYS ER profile page.
The generic ingredient in ADZENYS ER is amphetamine. There is one drug master file entry for this compound. Three suppliers are listed for this compound. Additional details are available on the amphetamine profile page.
The generic ingredient in ADZENYS ER is amphetamine. There is one drug master file entry for this compound. Three suppliers are listed for this compound. Additional details are available on the amphetamine profile page.
Summary for 204325
| Tradename: | ADZENYS ER |
| Applicant: | Neos Theraps Inc |
| Ingredient: | amphetamine |
| Patents: | 3 |
Medical Subject Heading (MeSH) Categories for 204325
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | SUSPENSION, EXTENDED RELEASE;ORAL | Strength | EQ 1.25MG BASE/ML | ||||
| Approval Date: | Sep 15, 2017 | TE: | RLD: | Yes | |||||
| Patent: | ⤷ Start Trial | Patent Expiration: | Jun 28, 2032 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patent: | ⤷ Start Trial | Patent Expiration: | Jun 28, 2032 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patent: | ⤷ Start Trial | Patent Expiration: | Jun 28, 2032 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Complete Access Available with Subscription
